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Abstract
Background. Drug-resistant tuberculosis (TB) is a serious threat in industrialized coun-
tries, but information from Southern Italy is lacking. Here, we present the results of a 
retrospective study of TB cases diagnosed in 2008-2013 in Naples, the largest city in 
Southern Italy.
Methods. Six hundred ninety Mycobacterium tuberculosis strains were isolated at the Os-
pedali dei Colli of Naples, and resistance to first-line and second-line drugs was deter-
mined. 
Results. Multidrug-resistant (MDR) TB increased from 2008 to 2013, with 77.4% of 
strains isolated from migrants from 41 countries. Overall, 4.5% of strains were MDR: 
Italian-born persons, 2.2%; Romania, 7.5%; Former Soviet Union countries (Ukraine, 
Russia, Armenia, Georgia), 22.4%; all other foreign countries, 2.0%. Resistance of MDR 
strains to second-line drugs was high against kanamycin, ofloxacin, capreomycin.
Conclusions. MDR-TB in Naples increased in 2008-13 and was observed predominant-
ly in migrants, indicating the need to intensify diagnosis and treatment of these popula-
tions in this town.
INTRODUCTION
Tuberculosis (TB) still remains a major infectious dis-
ease worldwide. In recent years, TB caused by multi-
drug-resistant (MDR) Mycobacterium tuberculosis strains 
(i.e. resistant to at least isoniazid, H, and rifampin, R) 
and extensively drug-resistant (XDR) strains (i.e. MDR 
strains resistant to any fluoroquinolone and to at least 
one injectable drug: kanamycin, KM; capreomycin, 
CM; amikacin, AK) is becoming a public health con-
cern in all industrialized countries due to increasing mi-
gration from regions where TB is endemic [1]. Fifteen 
of the 27 high MDR-TB burden countries worldwide 
are in the European Region [2]. Population mobility is 
a main factor in globalization of several drug-resistant 
organisms and plays an important role in TB epidemi-
ology in the EU/EEA [3]. The highest proportions of 
MDR-TB cases and the most severe drug-resistance 
patterns were observed in the countries of the Former 
Soviet Union (FSU). From 2008-2014, 2.6% of a total 
of M. tuberculosis strains in Italy were isolated from pa-
tients whose country of birth was in the FSU [4, 5].
In our country, the number of reported TB cases 
decreased from 4246 in 1990 to 3153 in 2013, corre-
sponding to 5.3 cases per 100 000 population, but the 
proportion of notifications from people born abroad 
consistently increased in the last decades from 22% in 
1999 to 46% in 2008 and 63% in 2013 [6, 7]. In 2008, 
almost two-thirds of TB cases in foreigners occurred in 
Northern Italy [8]. Less information is available from 
Southern Italy [9], with lower data for this part of the 
country likely due to under-notification [10]. Only one 
study reported the TB incidence in 1996-2000 for mi-
grants living in Naples, the largest city in Southern Italy 
and county seat of the region of Campania [10]. In 
2008, the incidence of TB in Italian-born (IB) and for-
eign-born (FB) persons in Campania was about 2 and 
42 cases per 100 000 people, respectively [7]. In 2013, 
989 111 people lived within the Neapolitan administra-
tive limits [11] and the metropolitan area had a popula-
tion of more than 3 million inhabitants.
The aim of the present study was to perform a ret-
rospective investigation of microbiologically-confirmed 
TB cases diagnosed in 2008-2013 in a laboratory cover-
ing a part of the metropolitan area of Naples, to provide 
updated information on drug-resistance proportions 
and drug-resistance profiles of M. tuberculosis strains 
circulating among IB and FB patients.
MATERIALS AND METHODS
The study was conducted at the Laboratory of Micro-
biology and Virology of the Ospedali dei Colli, Naples. 
The Ospedali dei Colli is a consortium of three public 
Address for correspondence: Giulia Santoro, Laboratorio di Microbiologia e Virologia, Ospedali dei Colli, Via L. Bianchi 5, 80131 Naples, Italy. E-mail: 
giulia_santoro@hotmail.com.
Annalisa Del Giudice, Alessandro Mustazzolu, Angelo Iacobino et al.
B
r
ie
f
 N
o
t
e
s
604
hospitals (Monaldi, Cotugno and CTO) with 14 beds 
for TB patients in the Cotugno hospital. Demographic 
data of patients were obtained from medical records. 
Any case with a positive culture for M. tuberculosis was 
considered microbiologically-confirmed TB. Specimens 
collected from patients admitted to the hospital were 
routinely examined from 1 January 2008 to 31 Decem-
ber 2013 by smear microscopy, and cultured using solid 
media (Löwenstein-Jensen, Becton Dickinson, Sparks, 
MD, USA) and liquid media (MGIT 960; Becton Dick-
inson), according to known guidelines [12]. Identifica-
tion of M. tuberculosis strains was performed by the Gen-
oType Mycobacterium CM molecular genetic assay (Hain 
Lifescience, Nehren, Germany) and/or the BD MGIT 
TBc Identification assay (Becton Dickinson). Drug sus-
ceptibility testing (DST) to first-line drugs (FLD) strep-
tomycin (S), H, R, ethambutol (E), and second-line 
drugs (SLD) KM, AK, CM, ofloxacin (OFL) was per-
formed by the MGIT 960 system (Beckton Dickinson), 
using the following critical concentrations: 1.0, 0.1, 1.0, 
5.0, 2.5, 1.0, 2.5, 2.0 µg/ml, respectively [13]. In case 
of M. tuberculosis strains identified as MDR or XDR by 
the MGIT 960 system, resistance to H and R was con-
firmed by the GenoType MTBDRplus assay (Hain) and 
resistance to aminoglycosides/cyclic peptides, fluoroqui-
nolones and E by the MTBDRsl assay (Hain). 
The Laboratory of Microbiology and Virology partici-
pated in the drug susceptibility proficiency testing of 
the Istituto Superiore di Sanità, Rome [14] and ≥ 90% 
agreement for FLD and SLD was achieved in 2010 and 
2013.
RESULTS
In the period 2008-2013, 690 M. tuberculosis strains 
(115.0 ± 9.5 per year) were isolated from primary cul-
tures from 690 different patients (76.4% of new cases 
and 23.6% of previously treated cases) and character-
ized for resistance to FLD and SLD. 
The age of patients was as follows: mean, 41.9 ± 17.3 
years; median, 37 years; range, 1-89 years. In the six 
years of the study, 482 TB cases occurred in males (69.9 
± 2.3%: 262 FB and 220 IB persons) and 208 in females 
(30.1 ± 2.3%: 100 FB and 108 IB persons) (Figure 1A). 
Three hundred and twenty-two cases (46.7%) were di-
agnosed in IB persons and 368 (53.3%) in FB persons 
(Europe: 27.4%, Africa: 16.1%; Asia: 7.6%; the Ameri-
cas: 2.2%). The top-five countries contributing to the FB 
group were Romania (32.7%), Ukraine (11.2%), Mo-
rocco (10.3%), Nigeria (4.7%), Pakistan (4.2%). The FB 
persons were younger than IB persons (33.7 ± 10.6 versus 
49.5 ± 19.7 years; P < 0.001, Student’s t test) and arrived 
from 41 countries. Tuberculosis in children (≤ 5 years) 
occurred in 9 cases including 6 in IB persons (1, 1, 1, 2, 
5, 5 years) and 3 in children (2, 5, 5 years) born in Italy 
from FB parents. The latter cases were included in the 
FB group due to the close contacts with their parents.
As to drug resistance, out of 690 strains tested 144 
(66.9% of new cases and 33.1% of previously treated 
cases) showed resistance to FLD (Table 1). While the 
rate of MDR strains isolated in 2008-2013 (Figure 1B) 
from IB patients remained stable at around 1% of the 
cases, in the same period the rate of MDR strains iso-
lated from FB patients increased from about 2% to 4%. 
To evaluate drug-resistance proportions and profiles, we 
stratified data of M. tuberculosis strains isolated from FB 
patients in three groups including Romania (the larg-
est group from a single country), FSU countries (the 
highest MDR-TB group) and all other foreign coun-
tries, in comparison with data of IB strains (Table 1). 
The proportion of strains resistant to FLD isolated from 
patients born in the FSU countries (44.9%, 22 strains) 
was higher than that observed in IB persons and in the 
other two FB groups. The FSU countries of origin of 
the 22 FLD resistant strains were: Ukraine, 15; Russia, 
4; Georgia, 2; Armenia, 1. In the FSU-group the rates 
of resistance to S (32.7%) and H (36.7%) were higher 
Figure 1
Trend of TB cases in male, female, foreign-born (FB) persons, Italian-born (IB) persons (A), and of MDR-TB cases in FB and IB persons 
(B) in Naples, in the period 2008-2013.
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than those to R and E. Monoresistance of FSU-strains 
to S and R was 4.1% and no monoresistance to H and 
E was seen.
Out of the 690 M. tuberculosis strains examined, 31 
(4.5%) were MDR strains, including 24 (77.4%) from 
FB persons. Large differences among the three groups 
were observed, with a very high MDR rate in people 
coming from the FSU countries (22.4%) and lower 
levels in the other groups. Eleven MDR strains were 
isolated from FSU countries (Ukraine, 6; Russia, 3; 
Armenia, 1; Georgia, 1) and 20 from other countries 
(Romania, 9; Morocco, 2; Sri-Lanka, 1; India, 1; Italy, 
7). The FB persons with MDR-TB were younger than 
IB persons [26.8 ± 12.1 (median 27.5) years versus 49.7 
± 19.3 (median 47) years; P < 0.001]. As to FLD com-
binations, 27 out of 31 MDR strains were resistant to 
three drugs. The MDR strains isolated from the FSU 
countries were more resistant to SHR and SHRE than 
to HR and HRE. 
Among MDR strains tested for susceptibility to SLD 
(7 from IB and 24 from FB patients), a high propor-
tion (48.4%) of strains were resistant to KM, followed 
by OFL (38.7%), CM (35.5%), AK (12.9%). Five 
MDR isolates (16.1%) were XDR strains (2 each from 
Ukraine and IB patients, and 1 from Morocco).
DISCUSSION
Tuberculosis is slowly declining globally at about 1.5% 
per year [4] but in industrialized countries a decreasing 
incidence in the native population is often associated 
Table 1
Antituberculosis drug resistance in 690 Mycobacterium tuberculosis strains isolated in Naples from Italian-born (IB) and foreign-born 
(FB) persons in the period 2008-2013
IB FBs from: Total no.
   (%)
Romania  
(%)
FSUa  
(%)
All other foreign countries
(%)
 
(%)
Total tested 322 (100.0) 120 (100.0) 49 (100.0) 199 (100.0) 690 (100.0)
Resistance to FLDb 65 (20.2) 15 (12.5) 22 (44.9) 42 (21.1) 144 (20.9)
Monoresistance      
S 30 (9.3) 2 (1.7) 2 (4.1) 15 (7.5) 49 (7.1)
H 9 (2.8) 4 (3.3) 0 (0.0) 13 (6.5) 26 (3.8)
R 1 (0.3) 0 (0.0) 2 (4.1) 0 (0.0) 3 (0.4)
E 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Any resistance      
S 50 (15.5) 11 (9.2) 16 (32.7) 29 (14.6) 106 (15.4)
H 33 (10.3) 13 (10.8) 18 (36.7) 27 (13.6) 91 (13.2)
R 9 (2.8) 9 (7.5) 13 (26.5) 4 (2.0) 35 (5.1)
E 4 (1.2) 0 (0.0) 12 (24.5) 4 (2.0) 20 (2.9)
MDRc 7 (2.2) 9 (7.5) 11 (22.4) 4 (2.0) 31 (4.5)
SHRE 2 (0.6) 0 (0.0) 7 (14.3) 2 (1.0) 11 (1.6)
SHR 1 (0.3) 9 (7.5) 3 (6.1) 2 (1.0) 15 (2.2)
HRE 0 (0.0) 0 (0.0) 1 (2.0) 0 (0.0) 1 (0.2)
HR 4 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.6)
Other resistances
HS 15 (4.7) 0 (0.0) 3 (6.1) 8 (4.0) 26 (3.8)
HSE 1 (0.3) 0 (0.0) 1 (2.0) 2 (1.0) 4 (0.5)
HE 1 (0.3) 0 (0.0) 3 (6.1) 0 (0.0) 4 (0.6)
RE 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
RS 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2)
RES 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Resistance of MDR 
strains to SLDd 7 (100.0) 9 (100.0) 11 (100.0) 4 (100.0) 31 (100.0)
KM 2 (28.6) 6 (66.7) 5 (45.5) 2 (50.0) 15 (48.4)
OFL 3 (42.9) 1 (11.1) 7 (63.6) 1  (25.0) 12 (38.7)
CM 3 (42.9) 0 (0.0) 4 (36.4) 4 (100.0) 11 (35.5)
AK 0 (0.0) 0 (0.0) 2 (18.2) 2 (50.0) 4 (12.9)
aFSU: Former Soviet Union countries (Ukraine, Russia, Armenia, Georgia).
bFLD: first-line drugs. S, streptomycin; H, isoniazid; R, rifampin; E, ethambutol.
cMDR: multidrug-resistant (resistant to at least H and R).
dSLD: second-line drugs. KM, kanamycin; OFL, ofloxacin; CM, capreomycin; AK, amikacin. 
Values in parenthesis are the percentages of MDR strains.
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with an increase of TB notifications in FB patients [5, 
8, 15-17].
Our study is the first report on the microbiological 
and epidemiological trends of drug-resistant TB in Na-
ples, the largest city in Southern Italy. It is known that 
FB residents in Naples and in the region Campania 
were 1.7% and 1.6% of the total populations in 2005, 
2.5% and 2.3% in 2008, 3.5% and 4.8% in 2013, respec-
tively [11] but a consistent rate of illegal migrants was 
also reported [10]. In 2013, the top-five native countries 
of FB residents in Naples were Sri-Lanka, Ukraine, 
China, Romania and Philippines, and in Campania 
were Ukraine, Romania, Morocco, Sri-Lanka and Chi-
na. Overall, in 2008-2013 the number of M. tuberculosis 
strains annually isolated in our laboratory from IB and 
FB patients was quite stable. As previously reported for 
TB patients at a national level [5, 15], FB persons at 
Naples were significantly younger that IB persons. The 
observation that microbiologically-confirmed TB cases 
occurred mostly in migrants from Romania, Ukraine 
and Morocco is in keeping with nationality rates of FB 
residents in Naples/Campania and consistent with a 
high prevalence of TB in their native countries (e.g., Ro-
mania, 99; Ukraine, 114; Morocco, 137 cases per 100 
000 population) [18]. 
Our data showed that the MDR-TB increase in the 
FB patients paralleled the increase in immigration rate 
reported for Naples and Campania [11] in the six years 
of the study. Over 60% of MDR-TB cases occurred in 
young male migrants coming from the FSU countries 
(Ukraine, Russia, Armenia, Georgia) and Romania. 
These FSU countries are all included in the WHO list 
of 27 high MDR-TB burden countries [4]. The contri-
bution of FSU countries to MDR-TB in Naples/Cam-
pania was higher (11/31 strains, i.e. 35.5%) than that 
observed at national level (29.8%) in 2008-2014 [5]. 
The high MDR-TB prevalence in FB patients was also 
consistent with that of their native countries (e.g. in 
2013: Ukraine, 21.8%; Russia, 33.5%; Armenia, 15.0%; 
Georgia 17.7%; Romania, 7.8%) [6]. The low propor-
tion of African-born persons with MDR-TB (2 out of 
31 cases from Morocco) is also in keeping with recent 
national observations [5], likely due to the fact that 
for many years Africa was neglected and TB was not 
treated, and that fixed-dose combinations were widely 
used in that continent [5, 19, 20]. The contribution of 
MDR M. tuberculosis strains isolated from IB patients 
was relatively low (2.2%) but higher than that seen at 
national level (1.2% in 2008-2014 [5]). 
When MDR M. tuberculosis strains were tested for 
susceptibility to SLD, the percentages of resistance to 
the injectable drugs KM and CM and the fluoroquino-
lone OFL were very high while resistance to AK was 
low, but the number of strains examined was small, 
making it difficult to draw conclusions. It is important 
to point out that five MDR were XDR strains and that 
two of them were isolated from IB patients. These ob-
servations indicated that in Naples TB is an ongoing 
threat and that we must not lower our guard against this 
difficult-to-treat disease. 
Overall, our data indicated that in 2008-2013 more 
than half of patients with TB belonged to the FB group. 
This pattern is different from that previously reported in 
Naples in 1996-2000 [10]. In that study FB notifications 
were 14.3% of total cases, with Africans being the largest 
group (9.4%) and people from East Europe the smallest 
one (1.4%). Now, after more than ten years from that in-
vestigation, the proportions of TB patients substantially 
changed, with Africans being 16.1% of cases and Eu-
ropeans 27.4%, mostly arriving from Romania. Further-
more, large differences in MDR-TB rates between IB 
patients (2.2%) and people coming from FSU countries 
(22.4%), particularly Ukraine, were observed. A possible 
limit of this study is the fact that the diagnostic coverage 
of the large metropolitan area of Naples by our labora-
tory was partial. We tried to control the bias by stratify-
ing TB cases in different groups. In 2014, ECDC stated 
that the odds of harboring MDR-TB in FB patients in 
the WHO European Region was greater than that of 
natives, and in ten countries including Italy this was 
statistically significant [21]. As observed at the national 
level [5], migrants from countries with medium and high 
risk of TB retained their risk of developing MDR dis-
ease even after moving to low endemic areas. Thus, our 
observations are in keeping with national and European 
data and strongly indicate the need to intensify efforts 
to make local TB diagnosis and treatment services more 
and more accessible to migrant populations living in 
Naples together with IB persons. It is also important to 
understand how migrants perceive TB and the specific 
obstacles they face when accessing the health systems, 
seeking a diagnosis and adhering to a treatment pro-
gramme. In Italy, several types of accomodation centres 
for migrants have been recently created for screening TB 
and other infectious diseases [22, 23].  
CONCLUSIONS
Overall, our data showed that in Naples the MDR-
TB increased from 2008 to 2013 and that it occurred at 
rates reflecting those in the countries of origin. These 
epidemiological observations need to be taken into 
account in order to use all available tools to rapidly 
identify drug-resistant M. tuberculosis strains and begin 
treatment of TB patients. This approach will decrease 
transmission of the disease in a city with known socio-
economic problems and a high population density [10, 
11], under the WHO vision of improving TB control 
and eventually eliminating it as a public health problem 
by 2035 [1]. 
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